一种产酶溶杆菌SYSU923及其应用
By combining enzyme-producing lysobacterium SYSU923 with immune checkpoint inhibitors, the immune response was enhanced, addressing the problem of poor efficacy in existing treatments and achieving significant inhibition of esophageal cancer and metastasis.
CN120098833BActive Publication Date: 2026-07-17SUN YAT SEN UNIV
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- SUN YAT SEN UNIV
- Filing Date
- 2025-02-24
- Publication Date
- 2026-07-17
AI Technical Summary
Technical Problem
Existing PD-1/PD-L1 antibody therapies are effective in only 20-45% of esophageal cancer patients, and further optimization of treatment strategies is needed to improve treatment outcomes.
Method used
The combined use of enzyme-producing lysobacterium SYSU923 and its culture with immune checkpoint inhibitors enhances the anti-tumor response of immune cells and improves the therapeutic effect of immune checkpoint inhibitors.
Benefits of technology
It significantly inhibits the in situ growth and metastasis of esophageal cancer tumors, improves the therapeutic effect of immune checkpoint inhibitors, and provides a more effective treatment strategy for esophageal cancer.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure CN120098833B_ABST
Abstract
本发明属于微生物技术领域，具体涉及一种产酶溶杆菌SYSU923及其应用。本发明从土壤样本中经过平板抑菌圈法培养分离、纯化得到一种具有广谱抑菌活性的优势菌株产酶溶杆菌SYSU923，通过革兰氏染色、显微镜镜检、单菌落形态观察以及分子生物学实验鉴定为产酶溶杆菌Lysobacter enzymogenes，本发明通过使用产酶溶杆菌SYSU923或其培养物联合免疫检查点抑制剂，对食管癌植瘤小鼠进行抗肿瘤治疗，发现产酶溶杆菌SYSU923在增强免疫检查点抑制剂治疗效果方面具有显著作用，通过联合治疗，不仅能够有效抑制肿瘤在原位的生长，还显著减少肿瘤细胞的转移，有望为食管癌患者提供更为有效的治疗策略。
Need to check novelty before this filing date? Find Prior Art